扶正化瘀法防治肾纤维化的研究进展  

Research progress of Fuzheng Huayu method on the prevention and treatment of renal fibrosis

作　　者：秦军燕[1] 王琛[1] 

机构地区：[1]上海中医药大学附属曙光医院肾病科、上海市教委创新团队、肝肾疾病病证教育部重点实验室(上海中医药大学),上海200021

出　　处：《中华中医药杂志》2014年第10期3180-3183,共4页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家自然科学基金(No.30973723)~~

摘　　要：正虚血瘀是肾纤维化的主要病机,贯穿于肾纤维化始终。文章将近5年来中医药扶正化瘀法防治肾纤维化的实验研究进行归类,主要为:益气与活血兼施、益气与破血兼施、益气与活血泄浊兼施、温阳与活血兼施、补脾肾与活血解毒兼施。这些组合均可不同程度抑制肾脏细胞外基质(ECM)沉积,其作用途径为多靶点,存在一定的共性和差异性。但药物选择、配伍比例等因素的差异使得各研究之间疗效缺乏可比性,因此开展各种配伍方案比较研究,进一步精化药物选择、确定药用比例,仍然是下一步研究的方向。Deficiency of qi and blood stasis are the main pathogenesis of renal fibrosis which runs through the course of renal fibrosis. According to the experimental studies in nearly five years, TCM Fuzheng Huayu method of prevention and treatment of renal fibrosis are classified in this paper, including benefiting qi for activating blood circulation, benefiting qi and breaking blood, benefiting qi for activating blood circulation and clearing away turbidness, warming yang and activating blood circulation, reinforcing the spleen and kidney and activating blood circulation and detoxification,these combinations could inhibit the accumulation of ECM in kidney in a varied extent, there are some similarities and differences through multiple pathways.However, the differences in drug selection, compatibility proportion and other factors make the studies lack of comparability. So it is necessary to study and carry out the comparative studies of various compatibility proportion, further refinement of drug selection, making a determination of the medicinal proportion, which is still the direction of future research.

关 键 词：肾纤维化 扶正化瘀 中医药 

分 类 号：R277.5[医药卫生—中医学]